Format

Send to

Choose Destination
Pediatr Blood Cancer. 2014 Apr;61(4):737-9. doi: 10.1002/pbc.24761. Epub 2013 Sep 9.

Sustained remission of severe Multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.

Author information

1
Division of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, Minnesota.

Abstract

Castleman disease is a rare lymphoproliferative disorder, which presents in a unicentric or multicentric fashion. Multicentric Castleman disease (MCD) is associated with significant systemic symptoms, in part related to the underlying role of interleukin-6 in disease pathogenesis. Treatment for MCD has not been well established and prognosis has historically been poor. We present a case of severe MCD in a pediatric patient who has shown sustained remission following multi-agent chemotherapy and targeted maintenance therapy with the interleukin-6 receptor inhibitor, tocilizumab. This represents the first case report of sustained remission of MCD in a pediatric patient following discontinuation of tocilizumab therapy.

KEYWORDS:

CHOP; anakinra; multicentric Castleman disease; tocilizumab

PMID:
24019247
PMCID:
PMC3946294
DOI:
10.1002/pbc.24761
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center